Myocardial Ischemia-Reperfusion Injury
Conditions
Brief summary
This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress/inflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2/octanal/inflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.
Interventions
DIAGNOSTIC_TESTBlood Biomarker Profiling and Prognostic Follow-up
Peripheral venous blood collection for in-vitro quantification of serum biomarkers (including octanal, OR6A2, and inflammatory mediators) via mass spectrometry/ELISA/flow cytometry, coupled with longitudinal surveillance of Major Adverse Cardiovascular Events (MACEs) using hospital records, patient interviews, and adjudicated endpoint verification during scheduled follow-up visits.
Sponsors
Southeast University, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period. 2. Age 18-90 years inclusive.
Exclusion criteria
1. Active systemic infections. 2. Advanced heart failure (NYHA class III-IV). 3. Acute cerebrovascular conditions. 4. Active myocarditis. 5. cardiomyopathy. 6. Refractory ventricular tachycardia/fibrillation. 7. Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ). 8. Severe renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73m2 or dialysis dependence). 9. Child-Pugh class C hepatic dysfunction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Cardiovascular Events | From enrollment to 44 months after reperfusion injury | Major Adverse Cardiovascular Events (MACEs) defined as the composite endpoint of recurrent acute myocardial infarction, cardiac death, stroke, hospitalization for unstable angina, or unplanned coronary revascularization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum IL-1α Level | Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury) | Units: pg/mL |
| Serum IL-1β Level | Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury) | Units: pg/mL |
| Plasma Malondialdehyde (MDA) Level | Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury) | Units: μmol/L |
| Plasma Hydrogen Peroxide (H₂O₂) Level | Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury) | Units: μmol/L |
Countries
China
Contacts
Primary ContactWenbin Lu, PhD
Backup ContactYahao Zhang, M.D.
Outcome results
None listed